Download by
Scanning QR Code
No Data
US Stock MarketDetailed Quotes
DSKYF DAIICHI SANKYO COMPANY LIMITED
Watchlist
28.270
-0.080-0.28% Close 09/29 16:00 ET
28.580High26.990Low1.60KVolume
28.420Open28.350Pre Close45.15KTurnover0.00%Turnover Ratio53.14P/E (TTM)54.20BMarket Cap37.91052wk High66.05P/E (Static)1.92BShares25.69052wk Low5.28P/B54.20BFloat Cap37.910Historical High0.21Dividend TTM1.92BShs Float17.610Historical Low0.74%Div YieldTTM5.61%Amplitude28.163Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About DAIICHI SANKYO COMPANY LIMITED Company
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
News
US stocks closed | US stocks stopped falling for four consecutive years, chip stocks took the lead, and Arm rose more than 6%; Chinese securities weakened, and Ideal Auto fell nearly 10%
Investors continue to digest the prospect of European and American central banks “maintaining high interest rates for a longer period of time,” and Moody's warned that the US government shutdown next week would damage credit ratings. The 10-year and 30-year US Treasury yields were the highest since 2007 and 2011.
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) released topline data from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan (Dato-DXd) in previously treated patie
AstraZeneca, Daiichi Post Early Win in Phase 3 Trial for Breast Cancer Therapy